Adenomyosis and fatty liver disease are two distinct chronic conditions affecting different organ systems—the uterus and the liver respectively—yet they can occur together in some individuals. Adenomyosis involves endometrial tissue growing into the muscular wall of the uterus, causing heavy periods, pelvic pain, and dysmenorrhoea. Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), occurs when excess fat accumulates in liver cells and affects approximately one in three UK adults. Whilst there is no direct causal link between these conditions, emerging research suggests they may share common metabolic and inflammatory pathways, including obesity, insulin resistance, and chronic inflammation. Understanding how these conditions coexist and influence each other is important for effective management and improved health outcomes.

Understanding Adenomyosis and Fatty Liver Disease

Adenomyosis is a gynaecological condition in which endometrial tissue—the tissue that normally lines the uterus—grows into the muscular wall of the uterus (myometrium). This ectopic tissue continues to respond to hormonal changes during the menstrual cycle, causing inflammation, thickening of the uterine wall, and often significant symptoms. Women with adenomyosis commonly experience heavy menstrual bleeding (HMB), prolonged periods, severe pelvic pain, and painful periods (dysmenorrhoea). The condition typically affects women in their 30s and 40s, particularly those who have had children or previous uterine surgery, though it can occur at any reproductive age. Diagnosis is usually made through transvaginal ultrasound performed by an experienced sonographer, or magnetic resonance imaging (MRI) when further detail is needed. Definitive histological diagnosis is only possible after hysterectomy, but clinical and imaging findings are sufficient for diagnosis and management in most cases.

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. The two main types are non-alcoholic fatty liver disease (NAFLD), which affects people who drink little or no alcohol, and alcohol-related fatty liver disease. NAFLD is increasingly common in the UK, affecting approximately one in three adults to some degree. Most people with simple fatty liver have no symptoms, and the condition is often discovered incidentally during routine blood tests or abdominal imaging. It is important to note that liver blood tests (liver function tests) can be entirely normal in NAFLD and should not be used alone to exclude the condition. In some individuals, NAFLD can progress to non-alcoholic steatohepatitis (NASH), characterised by liver inflammation and damage, which may eventually lead to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma.

Both conditions represent chronic inflammatory states affecting different organ systems—the reproductive system and the hepatobiliary system respectively. Whilst they appear unrelated at first glance, emerging research has noted their co-occurrence in some individuals, possibly through shared metabolic and inflammatory pathways. Understanding each condition individually provides the foundation for exploring how they might coexist in affected individuals.

Can Adenomyosis and Fatty Liver Occur Together?

There is no established direct causal link between adenomyosis and fatty liver disease, meaning one condition does not directly cause the other. However, both conditions can certainly occur simultaneously in the same individual. Some observational studies have noted a higher-than-expected co-occurrence, though the evidence base remains limited and the association is not yet fully understood. Any observed link appears to be related to shared underlying risk factors—such as obesity, metabolic syndrome, and age—rather than a direct pathophysiological connection between the uterus and liver.

Several population-based studies have identified that women with adenomyosis may have an increased prevalence of metabolic disorders, including NAFLD, but these findings require cautious interpretation due to potential confounding factors. One proposed explanation centres on chronic systemic inflammation—both conditions involve inflammatory processes that may be amplified by common metabolic disturbances. Adenomyosis creates a pro-inflammatory environment within the uterus, and it is hypothesised that inflammatory mediators may enter systemic circulation. Similarly, NAFLD is associated with chronic low-grade inflammation and insulin resistance, which contribute to metabolic syndrome.

The hormonal environment may also play a role in this association. Adenomyosis is an oestrogen-dependent condition, and oestrogen metabolism occurs primarily in the liver. It has been suggested that women with fatty liver may have altered oestrogen metabolism, potentially influencing the development or progression of oestrogen-sensitive conditions like adenomyosis, though this remains a hypothesis. Additionally, obesity—a major risk factor for NAFLD—is associated with increased peripheral conversion of androgens to oestrogens in adipose tissue, creating a state of relative oestrogen excess.

It is important to emphasise that having one condition does not mean you will inevitably develop the other. The co-occurrence reflects overlapping risk profiles rather than a guaranteed progression. Healthcare professionals should maintain awareness of this potential association when managing patients with either condition, particularly in the presence of metabolic risk factors.

Shared Risk Factors and Underlying Mechanisms

Several metabolic and lifestyle factors increase the risk of developing both adenomyosis and fatty liver disease, though the strength of evidence differs between the two conditions. Obesity stands out as a particularly significant risk factor for NAFLD and is strongly associated with its development and progression. In adenomyosis, the role of obesity is less well established, but excess body weight contributes to chronic inflammation and hormonal imbalance, with increased aromatase activity in adipose tissue leading to elevated oestrogen levels that may promote endometrial tissue growth within the myometrium.

Insulin resistance and metabolic syndrome represent another crucial connection, particularly for NAFLD. Metabolic syndrome—characterised by central obesity, hypertension, dyslipidaemia, and impaired glucose metabolism—is a well-established risk factor for NAFLD. Emerging evidence suggests that insulin resistance may also play a role in adenomyosis pathogenesis, possibly through effects on inflammatory pathways and hormonal regulation, though this link is not yet proven. Women with polycystic ovary syndrome (PCOS), a condition characterised by insulin resistance and hormonal imbalance, show increased rates of NAFLD; any association between PCOS and adenomyosis is less certain and requires further research.

Chronic inflammation has been proposed as a unifying mechanism linking these conditions. NAFLD is characterised by elevated inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). Whether adenomyosis produces similar systemic inflammatory changes remains uncertain, though local uterine inflammation is well documented. This systemic inflammatory state may create a self-perpetuating cycle, where inflammation in one organ system contributes to inflammatory processes elsewhere in the body.

Dietary factors influence NAFLD significantly. Diets high in refined carbohydrates, saturated fats, and processed foods promote insulin resistance, weight gain, and hepatic fat accumulation. Whether these same dietary patterns directly exacerbate adenomyosis symptoms is not well evidenced, though anti-inflammatory dietary approaches—such as Mediterranean-style eating patterns rich in vegetables, fruits, whole grains, and omega-3 fatty acids—may support overall metabolic health and symptom management.

Age and reproductive history also matter. Recognised risk factors for adenomyosis include increasing age (particularly 30s and 40s), multiparity (having had children), and prior uterine surgery (such as caesarean section or myomectomy). NAFLD prevalence increases with age and is particularly common in post-menopausal women, when protective effects of oestrogen on metabolic health diminish.

Managing Both Conditions: Treatment Approaches

When adenomyosis and fatty liver disease coexist, management requires a coordinated, multidisciplinary approach addressing both conditions whilst considering potential treatment interactions. The cornerstone of management for both conditions involves lifestyle modification, making this an ideal starting point for integrated care.

Lifestyle interventions form the foundation of treatment for NAFLD and can support overall health in adenomyosis. Weight loss of 7–10% of body weight has been shown to improve or resolve NAFLD in many patients and may also reduce systemic inflammation and oestrogen levels. A structured programme combining dietary modification with regular physical activity is recommended. UK Chief Medical Officers' guidance suggests aiming for at least 150 minutes of moderate-intensity aerobic activity weekly, alongside muscle-strengthening activities. Dietary advice should focus on reducing refined carbohydrates and saturated fats whilst increasing fibre, vegetables, and lean proteins.

Pharmacological management of adenomyosis must be carefully considered in the context of liver disease. Treatment options for heavy menstrual bleeding and pain include:

• Tranexamic acid: A first-line non-hormonal treatment for heavy menstrual bleeding (per NICE NG88). It is generally well tolerated and can be used in liver disease, though caution is advised in advanced cirrhosis due to theoretical thrombotic risk.

• Levonorgestrel intrauterine system (LNG-IUS): This represents an excellent first-line hormonal option as it delivers progestogen locally to the uterus with minimal systemic absorption. It effectively reduces menstrual bleeding and pain in many women with adenomyosis. However, the Summary of Product Characteristics (SmPC) lists acute liver disease and liver tumours as contraindications. In stable, non-cirrhotic fatty liver disease, the LNG-IUS is generally acceptable with appropriate clinical review. Discuss with your GP or gynaecologist.

• Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs): Paracetamol (within recommended daily limits) is first-line for pain relief. NSAIDs (such as ibuprofen or mefenamic acid) are helpful for dysmenorrhoea and can be used with standard cautions in uncomplicated NAFLD. However, NSAIDs should be avoided in advanced liver disease (cirrhosis) due to risks of renal impairment, fluid retention, and gastrointestinal bleeding. Always use the lowest effective dose for the shortest duration.

• Combined oral contraceptives and progestogen-only pills: These can be used for symptom control in adenomyosis. Safety in liver disease depends on the severity and type of hepatic impairment. The Faculty of Sexual and Reproductive Healthcare (FSRH) UK Medical Eligibility Criteria (UKMEC) provides detailed guidance: combined hormonal contraception is generally contraindicated in active or decompensated liver disease, whilst progestogen-only methods often have fewer restrictions. Your GP or gynaecologist will assess suitability based on your individual liver health.

• GnRH analogues: These medications induce a temporary menopausal state and can be effective for severe adenomyosis. Their use is typically limited to short courses (usually up to six months) due to side effects including vasomotor symptoms (hot flushes) and bone density loss. Add-back hormone replacement therapy may be considered under specialist supervision to mitigate these effects during longer treatment courses.

Management of fatty liver disease focuses primarily on addressing underlying metabolic factors through lifestyle change. There are currently no medicines licensed specifically for NAFLD in the UK. In specialist care, for patients with biopsy-proven non-alcoholic steatohepatitis (NASH) and significant fibrosis, pioglitazone or vitamin E may be considered off-label as per NICE NG49, following careful discussion of risks and benefits. GLP-1 receptor agonists (such as semaglutide) may be considered for weight management in appropriate patients and can offer benefits for NAFLD. Treatment of associated conditions—such as type 2 diabetes, hypertension, and dyslipidaemia—is essential and follows standard NICE guidance. Metformin, commonly used for diabetes and PCOS, may offer benefits for insulin resistance; however, evidence that metformin improves adenomyosis symptoms is lacking and it is not a recommended treatment for this indication.

Surgical options for adenomyosis may be considered when conservative management fails. Hysterectomy is the definitive treatment. Endometrial ablation is usually not recommended for adenomyosis, as it is often ineffective and may worsen pain; other uterine-sparing procedures such as uterine artery embolisation or adenomyomectomy may be considered in selected cases under specialist guidance. Pre-operative assessment should include liver function tests, and anaesthetic considerations may be necessary in patients with significant liver disease. Bariatric surgery may be appropriate for selected patients with severe obesity affecting both conditions, offering substantial benefits for NAFLD whilst potentially improving adenomyosis symptoms through weight loss and metabolic improvement.

Monitoring and follow-up should be coordinated between gynaecology and gastroenterology or hepatology services as appropriate. For NAFLD, NICE NG49 recommends non-invasive assessment of liver fibrosis using the Enhanced Liver Fibrosis (ELF) blood test or risk stratification tools (such as FIB-4 or NAFLD Fibrosis Score) in primary care, with referral to specialist services based on results. Liver function tests alone are insufficient, as they can be normal in NAFLD. Regular assessment should include metabolic parameters (HbA1c, lipid profile, blood pressure), adenomyosis symptom severity, treatment effectiveness, and full blood count to monitor for anaemia.

Reporting side effects: If you experience any side effects from your medicines, whether listed in the patient information leaflet or not, please report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This helps improve the safety of medicines for everyone.

When to Seek Medical Advice for These Conditions

For adenomyosis symptoms, you should contact your GP if you experience:

• Heavy menstrual bleeding requiring frequent pad or tampon changes (soaking through protection hourly), or periods lasting longer than seven days

• Severe pelvic pain or cramping that interferes with daily activities or is not adequately controlled by over-the-counter pain relief

• Pain during sexual intercourse (dyspareunia) that affects your quality of life

• Bleeding between periods

• Symptoms of anaemia, such as persistent fatigue, breathlessness, dizziness, or pale skin, which may result from chronic blood loss

Urgent referral is required for:

• Postmenopausal bleeding (any vaginal bleeding occurring 12 months or more after your last period): this requires urgent assessment under the NHS two-week-wait suspected cancer pathway (NICE NG12). Contact your GP immediately.

• Persistent intermenstrual bleeding, particularly if you have risk factors for endometrial cancer.

For potential fatty liver disease, seek medical advice if you have:

• Risk factors including obesity (particularly central adiposity), type 2 diabetes, high cholesterol, metabolic syndrome, or a family history of liver disease

• Abnormal liver function tests detected during routine blood work—though remember that liver blood tests can be normal in NAFLD

• Persistent fatigue or discomfort in the upper right abdomen, though these symptoms are uncommon in early NAFLD

Emergency medical attention (call 999 or attend A&E) is warranted if you develop:

• Severe, sudden abdominal pain that differs from your usual symptoms

• Very heavy vaginal bleeding with signs of haemodynamic compromise (dizziness, fainting, rapid heartbeat)

• Jaundice (yellowing of the skin or whites of the eyes), which may indicate significant liver dysfunction

• Signs of liver decompensation, including confusion, significant abdominal swelling (ascites), vomiting blood (haematemesis), or black, tarry stools (melaena)

Regular monitoring is important when managing both conditions. Your GP should coordinate care, which may involve:

• Non-invasive liver fibrosis assessment as per NICE NG49 (such as the Enhanced Liver Fibrosis [ELF] blood test or risk stratification using FIB-4/NAFLD Fibrosis Score), with referral to specialist hepatology services if indicated

• Periodic liver function tests, though these may be normal in NAFLD and should not be relied upon alone

• Assessment of metabolic parameters including HbA1c, lipid profile, and blood pressure

• Evaluation of adenomyosis symptom severity and treatment effectiveness

• Full blood count to monitor for anaemia

If you have been diagnosed with either condition, inform your healthcare provider about the other, as this may influence investigation and management strategies. Do not hesitate to seek advice if your symptoms worsen or if you have concerns about your treatment. Early intervention and consistent management significantly improve outcomes for both adenomyosis and fatty liver disease, and a proactive approach to your health is essential for long-term wellbeing.

Frequently Asked Questions